Show Menu

A fully integrated developer and manufacturer of polyclonal therapeutics, targeting infectious disease and acute toxic events

News: Latest Posts

Wellcome Grant for MicroPharm’s International Phase II Clinical Trial of C. diff. Infection treatment, OraCAb

Wales-based MicroPharm Limited (‘MicroPharm’) has been awarded funding of up to £2.8m from Wellcome to undertake a Phase II clinical trial of oral therapeutic drug, OraCAb®, for the treatment of non-life-threatening C. difficile infection (‘C. diff.’ or ‘CDI’).

Read the full story

Posted on: Wednesday, 8th May 2024

MicroPharm’s Cilgerran Manufacturing Site licensed by the MHRA

MicroPharm’s Cilgerran Manufacturing Site granted MIA, MIA (IMP) and “Specials” licences by the MHRA.

Read the full story

Posted on: Monday, 11th March 2024

Wellcome Trust Grant

MicroPharm Limited is pleased to announce that it has been awarded a grant by the Wellcome Trust to progress a project entitled “A Rapid and Substantial Increase in Supplies of an Effective, Safe and Affordable Antivenom to sub-Saharan Africa”. 

Read the full story

Posted on: Wednesday, 30th June 2021

Acquisition of Sanofi Pasteur’s Equine Antivenom Immunoglobulin Products

MicroPharm Limited is pleased to announce the acquisition of Sanofi Pasteur’s antivenom equine immunoglobulin product range comprising Viperfav®, Bothrofav® Scorpifav®, Fav-Afrique® and Favirept®.

Read the full story

Posted on: Tuesday, 2nd January 2018

MicroPharm Secures Biomedical Catalyst 2016 Grant

MicroPharm Limited announced that it has secured a grant of £195,567 to further support the development of OraCAb, a therapeutic for oral administration of polyclonal antibodies to treat Clostridium difficile infections.

Read the full story

Posted on: Wednesday, 1st February 2017